Synairgen (LON:SNG) Shares Down 17.7% – Should You Sell?

Synairgen plc (LON:SNG)’s share price was down 17.7% during trading on Tuesday . The company traded as low as GBX 0.80 ($0.01) and last traded at GBX 0.86 ($0.01). Approximately 933,123 shares were traded during mid-day trading, a decline of 38% from the average daily volume of 1,504,091 shares. The stock had previously closed at GBX 1.05 ($0.01).

Synairgen Price Performance

The company has a market capitalization of £8.45 million, a PE ratio of -0.52 and a beta of -2.23. The firm’s 50 day moving average is GBX 1.82 and its 200 day moving average is GBX 3.17.

About Synairgen

Synairgen is a respiratory drug discovery and development company founded by University of Southampton Professors Stephen Holgate, Donna Davies and Ratko Djukanovic. The business, focused primarily on lung viral defence in asthma and COPD, uses its differentiating human biology BioBank platform and world-renowned international academic KOL network to discover and develop novel therapies for respiratory disease.

Synairgen is conducting a double blind, placebo-controlled clinical trial in COVID-19 patients (SG016).